Silver Book

Silver Book Fact

TAVR Success in sSAS Patients

A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable, and 1.1% for those at intermediate surgical mortality risk.

Kodali S, Thourani V, White J, Malaisrie S, et al. Early Clinical and Echocardiographic Outcomes After SAPIEN 3 Transcatheter Aortic Valve Replacement in Inoperable, High-Risk and Intermediate-Risk Patients with Aortic Stenosis. Eur Heart J. 2016; 37: 2252-62. https://academic.oup.com/eurheartj/article/37/28/2252/2237654/Early-clinical-and-echocardiographic-outcomes

Reference

Title
Early Clinical and Echocardiographic Outcomes After SAPIEN 3 Transcatheter Aortic Valve Replacement in Inoperable, High-Risk and Intermediate-Risk Patients with Aortic Stenosis
Publication
Eur Heart J
Publication Date
2016
Authors
Kodali S, Thourani V, White J, Malaisrie S, et al.
Pages
2252-62
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Publications

Aortic Stenosis Fact Sheet

 https://www.silverbook.org/wp-content/uploads/2017/10/AS-FS-cover.png Thumbnail

Related Facts

  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • In 2010, ~67,500 SAVRs were performed in the U.S.
     
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…